Clinical validation of the psychotic depression assessment scale, hamilton depression rating scale-6, and brief psychiatric rating scale-5: Results from the clinical research center for depression study

Seon Cheol Park, Eun Young Jang, Jae Min Kim, Tae Youn Jun, Min-Soo Lee, Jung Bum Kim, Hyeon Woo Yim, Yong Chon Park

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

Objective The aim of this study was to validate the psychotic depression assessment scale (PDAS), which includes the six-item melancholia subscale from the Hamilton depression rating scale (HAMD-6) and the five-item psychosis subscale from the brief psychiatric rating scale (BPRS-5). Data from the Clinical Research Center for Depression (CRESCEND) study, which is a 52-week naturalistic trial, were analyzed. Methods Fifty-two patients with psychotic depression from the CRESCEND study met our inclusion criteria. The patients underwent the following psychometric assessments: the PDAS, including HAMD-6 and BPRS-5, the clinical global impression scales, the HAMD, the positive symptom subscale, and the negative symptom subscale. Assessments were performed at the baseline and then at weeks 1, 2, 4, 8, 12, 24, and 52. Spearman correlation analyses were used to assess the clinical validity and responsiveness of the PDAS. Results The clinical validity and responsiveness of the PDAS, including HAMD-6 and BPRS-5, were acceptable, with the exception of the clinical responsiveness of the PDAS for positive symptoms and the clinical responsiveness of BPRS-5 for negative symptoms. Conclusion The clinical relevance of the PDAS has been confirmed and this clinical validation will enhance its clinical utility and availability.

Original languageEnglish
Pages (from-to)568-576
Number of pages9
JournalPsychiatry Investigation
Volume14
Issue number5
DOIs
Publication statusPublished - 2017 Sep 1

Fingerprint

Brief Psychiatric Rating Scale
Depression
Research
Depressive Disorder
Psychometrics
Psychotic Disorders

Keywords

  • 5-item psychosis subscale
  • 6-item melancholia subscale
  • Clinical validation
  • Psychotic depression
  • Psychotic depression assessment scale

ASJC Scopus subject areas

  • Psychiatry and Mental health
  • Biological Psychiatry

Cite this

Clinical validation of the psychotic depression assessment scale, hamilton depression rating scale-6, and brief psychiatric rating scale-5 : Results from the clinical research center for depression study. / Park, Seon Cheol; Jang, Eun Young; Kim, Jae Min; Jun, Tae Youn; Lee, Min-Soo; Kim, Jung Bum; Yim, Hyeon Woo; Park, Yong Chon.

In: Psychiatry Investigation, Vol. 14, No. 5, 01.09.2017, p. 568-576.

Research output: Contribution to journalArticle

Park, Seon Cheol ; Jang, Eun Young ; Kim, Jae Min ; Jun, Tae Youn ; Lee, Min-Soo ; Kim, Jung Bum ; Yim, Hyeon Woo ; Park, Yong Chon. / Clinical validation of the psychotic depression assessment scale, hamilton depression rating scale-6, and brief psychiatric rating scale-5 : Results from the clinical research center for depression study. In: Psychiatry Investigation. 2017 ; Vol. 14, No. 5. pp. 568-576.
@article{4f93fd906bac4b738e364cae7479c27c,
title = "Clinical validation of the psychotic depression assessment scale, hamilton depression rating scale-6, and brief psychiatric rating scale-5: Results from the clinical research center for depression study",
abstract = "Objective The aim of this study was to validate the psychotic depression assessment scale (PDAS), which includes the six-item melancholia subscale from the Hamilton depression rating scale (HAMD-6) and the five-item psychosis subscale from the brief psychiatric rating scale (BPRS-5). Data from the Clinical Research Center for Depression (CRESCEND) study, which is a 52-week naturalistic trial, were analyzed. Methods Fifty-two patients with psychotic depression from the CRESCEND study met our inclusion criteria. The patients underwent the following psychometric assessments: the PDAS, including HAMD-6 and BPRS-5, the clinical global impression scales, the HAMD, the positive symptom subscale, and the negative symptom subscale. Assessments were performed at the baseline and then at weeks 1, 2, 4, 8, 12, 24, and 52. Spearman correlation analyses were used to assess the clinical validity and responsiveness of the PDAS. Results The clinical validity and responsiveness of the PDAS, including HAMD-6 and BPRS-5, were acceptable, with the exception of the clinical responsiveness of the PDAS for positive symptoms and the clinical responsiveness of BPRS-5 for negative symptoms. Conclusion The clinical relevance of the PDAS has been confirmed and this clinical validation will enhance its clinical utility and availability.",
keywords = "5-item psychosis subscale, 6-item melancholia subscale, Clinical validation, Psychotic depression, Psychotic depression assessment scale",
author = "Park, {Seon Cheol} and Jang, {Eun Young} and Kim, {Jae Min} and Jun, {Tae Youn} and Min-Soo Lee and Kim, {Jung Bum} and Yim, {Hyeon Woo} and Park, {Yong Chon}",
year = "2017",
month = "9",
day = "1",
doi = "10.4306/pi.2017.14.5.568",
language = "English",
volume = "14",
pages = "568--576",
journal = "Psychiatry Investigation",
issn = "1738-3684",
publisher = "Korean Neuropsychiatric Association",
number = "5",

}

TY - JOUR

T1 - Clinical validation of the psychotic depression assessment scale, hamilton depression rating scale-6, and brief psychiatric rating scale-5

T2 - Results from the clinical research center for depression study

AU - Park, Seon Cheol

AU - Jang, Eun Young

AU - Kim, Jae Min

AU - Jun, Tae Youn

AU - Lee, Min-Soo

AU - Kim, Jung Bum

AU - Yim, Hyeon Woo

AU - Park, Yong Chon

PY - 2017/9/1

Y1 - 2017/9/1

N2 - Objective The aim of this study was to validate the psychotic depression assessment scale (PDAS), which includes the six-item melancholia subscale from the Hamilton depression rating scale (HAMD-6) and the five-item psychosis subscale from the brief psychiatric rating scale (BPRS-5). Data from the Clinical Research Center for Depression (CRESCEND) study, which is a 52-week naturalistic trial, were analyzed. Methods Fifty-two patients with psychotic depression from the CRESCEND study met our inclusion criteria. The patients underwent the following psychometric assessments: the PDAS, including HAMD-6 and BPRS-5, the clinical global impression scales, the HAMD, the positive symptom subscale, and the negative symptom subscale. Assessments were performed at the baseline and then at weeks 1, 2, 4, 8, 12, 24, and 52. Spearman correlation analyses were used to assess the clinical validity and responsiveness of the PDAS. Results The clinical validity and responsiveness of the PDAS, including HAMD-6 and BPRS-5, were acceptable, with the exception of the clinical responsiveness of the PDAS for positive symptoms and the clinical responsiveness of BPRS-5 for negative symptoms. Conclusion The clinical relevance of the PDAS has been confirmed and this clinical validation will enhance its clinical utility and availability.

AB - Objective The aim of this study was to validate the psychotic depression assessment scale (PDAS), which includes the six-item melancholia subscale from the Hamilton depression rating scale (HAMD-6) and the five-item psychosis subscale from the brief psychiatric rating scale (BPRS-5). Data from the Clinical Research Center for Depression (CRESCEND) study, which is a 52-week naturalistic trial, were analyzed. Methods Fifty-two patients with psychotic depression from the CRESCEND study met our inclusion criteria. The patients underwent the following psychometric assessments: the PDAS, including HAMD-6 and BPRS-5, the clinical global impression scales, the HAMD, the positive symptom subscale, and the negative symptom subscale. Assessments were performed at the baseline and then at weeks 1, 2, 4, 8, 12, 24, and 52. Spearman correlation analyses were used to assess the clinical validity and responsiveness of the PDAS. Results The clinical validity and responsiveness of the PDAS, including HAMD-6 and BPRS-5, were acceptable, with the exception of the clinical responsiveness of the PDAS for positive symptoms and the clinical responsiveness of BPRS-5 for negative symptoms. Conclusion The clinical relevance of the PDAS has been confirmed and this clinical validation will enhance its clinical utility and availability.

KW - 5-item psychosis subscale

KW - 6-item melancholia subscale

KW - Clinical validation

KW - Psychotic depression

KW - Psychotic depression assessment scale

UR - http://www.scopus.com/inward/record.url?scp=85029767377&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85029767377&partnerID=8YFLogxK

U2 - 10.4306/pi.2017.14.5.568

DO - 10.4306/pi.2017.14.5.568

M3 - Article

AN - SCOPUS:85029767377

VL - 14

SP - 568

EP - 576

JO - Psychiatry Investigation

JF - Psychiatry Investigation

SN - 1738-3684

IS - 5

ER -